‘Game-changing' Alzheimer's drug could STOP disease in its tracks – as the ‘most powerful weapon' against condition yet
Scientists say the treatment - called trontinemab - could be the most powerful weapon yet against dementia, as they look into giving the drug to people with no symptoms in the hopes of preventing disease.
1
Phase two trial results for trontinemab were presented at he Alzheimer's Association International Conference in Toronto.
Researchers said the drug seemed to clear plaques - the abnormal build-up of proteins around brain cells that cause damage and disrupt function - quicker than other drugs licensed to treat Alzheimer's.
Trontinemab cleared out plaques and eliminated visible signs of the the disease within 28 weeks for nine out of 10 patients.
Drug-maker Roche is now conducting another trial to see if plaque clearance also improves patients' memory.
The 18-month study includes 1,600 people, the Telegraph reported.
Separate research will examine whether the drug could be given to people without any signs of dementia, just as statins are used to ward off heart disease.
Experts hope the drug could stop patients from developing dementia symptoms at all, if it is given early enough.
They described the findings so far as 'very promising', suggesting that the drug was much more powerful than existing ones while leading to fewer side effects - as it was able to clear plaques better within seven months that other drugs can in 18 months.
Roche's chief medical officer Levi Garraway said: 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics.
'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain.
"Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention.
"With plans for phase three trials in both early symptomatic and pre-clinical Alzheimer's disease, we are advancing science with the goal of delaying - and ultimately preventing - progression of this devastating condition.'
Prof Sir John Hardy, the chairman of molecular biology of neurological disease at University College London's Institute of Neurology told the Telegraph trontinemab could be 'game-changing'.
The scientist, who was the first to identify the role of amyloid plaques in Alzeheimer's, said: 'This is absolutely great news.
"It sucks the plaque out of the brain really quickly, much faster than we have seen with lecanemab or donanemab.'
Both are Alzheimer's drugs approved for used in the UK, which target amyloid proteins in the brain to slow disease progression.
However, neither treatment is offered on the NHS, as the National Institute for Health and Care Excellence (Nice) deemed them too expensive - in large part because patients need frequent scans to monitor for brain swelling and bleeds.
Prof Hardy added: 'There is no doubt [trontinemab] could be game-changing.
"We hope that if we can use these drugs to people early, we can halt the progression of disease, even before people have symptoms.
"Now we need to see the size of the clinical effect.
'These results show it is much faster and safer than previous drugs, which means less monitoring.
"That brings down the cost significantly, it means fewer MRI scans, so that would surely mean it would get Nice approval.'
Early signs of dementia
It's not unusual for your memory to lapse a bit as you get older.
But dementia is different from 'just getting old' as it will cause noticeable - rather than gradual - changes to mental abilities and make managing everyday tasks and activities increasingly difficult.
The symptoms of dementia may be small to start with, but get worse over time.
Below are some examples of possible signs.
Memory loss
Memory loss is a key sign of dementia. This can include:
Forgetting something you were only recently told. You may ask for the same information repeatedly – for example, 'Are the doors locked?'
Putting objects in unusual places – for example, putting your house keys in the refrigerator.
Being unable to learn new tasks, like how to use a new washing machine.
Planning and decision making issues
People with dementia can have difficulty with planning and decision making. This can include:
Getting very confused when planning or thinking things through.
Struggling to stay focused on a single task.
Not making informed, careful decisions when dealing with money or looking at risks.
Finding it hard to manage regular payments, budgets or monthly bills.
Problems with language and understanding
In people with dementia, this can manifest as:
Having frequent problems finding the right word or regularly referring to objects as 'that thing'.
Finding it hard to take part in conversations.
Regularly being unable to follow what someone is saying even without distractions.
Losing sense of time and place
Dementia can cause problems with orientation, including:
Losing track of the date, season or the passage of time.
Getting lost in a place that is familiar or that should be easy to find your way around – for example, a supermarket.
Regularly being unable to follow what someone is saying even without distractions.
Problems with vision and perception
This can mean having problems making sense of what you see.
For example, having difficulty judging distances on stairs, or mistaking reflections or patterns for other objects.
Mood and behavioural changes
Finally, dementia can also make people act differently or shift their mood. This can mean:
Becoming withdrawn and losing interest in work, friends or hobbies.
Feeling unusually sad, anxious, frightened or low in confidence.
Getting easily upset at home, at work, with friends or in places that usually feel comfortable or familiar.
Trials for lecanemab and donanemab showed the drugs helped clear toxic clumps out of the brain and slow nerve damage caused by Alzheimer's by 27 per cent and 35 per cent respectively, over the course of 18 months.
But the treatments did present a risk of brain swelling and brain bleeds, meaning patients needed intense monitoring.
Trontinemab appears to be safer and cause fewer side effects, with less than five per cent of patients showing abnormal results on their brain scans.
All of these cases were quickly resolved, researchers said.
The drug - administered by infusion into the bloodstream - also doesn't need to be given a frequently.
Upcoming trials will examine the impact of giving the drug to patients once a month for six months, then every three months.
Trontinemab has been designed to efficiently bypass the blood-brain barrier, a protective layer of cells that stops harmful substances in the blood stream from attacking the brain and spinal cord.
This barrier can make it hard for many drugs to reach the brain.
Prof Jonathan Schott, the chief medical officer at Alzheimer's Research UK, told the Telegraph: 'We urgently need a range of treatments for Alzheimer's that are effective and safe for the people affected by this devastating disease.
'Evidence presented at the Alzheimer's Association conference in Toronto on trontinemab is very promising, showing that the drug can effectively and rapidly clear amyloid from the brain, seemingly with very few side effects.
'We now need to see whether these early stage results carry through to later stage clinical trials, which are planned to start later this year, including in the UK.
"These trials will show whether the drug is not only safe, but impacts on memory, thinking and quality of life.'
He said it was 'exciting' that the drug would now be tested in some people without symptoms under the phase three trials.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
2 hours ago
- The Sun
I topped 51st after trying everything to stop my legs growing – but then I finally found a cure & it's not Mounjaro
A WOMAN topped a staggering 51st after trying everything to stop her legs growing before finally finding a cure that wasn't Mounjaro. Jameka Mauldin, a mum from the US, claimed she was a prisoner in her own body. 6 6 She piled on so much weight she had to rely on others to help her out of bed and even take her to the toilet. Jameka's health had gotten so bad, she feared every night might be her last. For years, the 35-year-old single mum struggled with swelling in her legs and lower body that didn't respond to any of the traditional weight loss advice. Jameka said: 'Doctors told me to eat less and move more, but no matter what I did, my legs just kept growing. 'It wasn't just fat. It felt different. It was heavy, tight, painful. I knew something was wrong.' So wrong, that Jameka's weight spiralled to 51 stone. But this remarkable woman fought back and has now shed over 25 stone. It was in 2019, she finally got the answers she'd been begging for. Jameka was diagnosed with lymphedema, a chronic condition that causes lymph fluid to build up in the body's soft tissue, leading to painful swelling, especially in the arms and legs. On top of that, she also had lipedema, a fat distribution disorder that typically affects women and is marked by the abnormal buildup of painful fat cells, particularly in the hips, thighs, and legs. 'Getting a diagnosis changed everything,' she said. 'I cried. Not because I was scared, but because I finally had a name for what I'd been going through all these years. 'Now I'm finally free. And I'm not just doing this for me, I'm doing it for every woman who's ever been dismissed, misdiagnosed, or told to just 'try harder'.' Both conditions are progressive and incurable, and sadly, both are often ignored or misdiagnosed, especially in black women. 'We're told we're just fat, or that we're lazy,' Jameka said. 'But this isn't about willpower. This is medical.' Lymphedema occurs when the body's lymphatic system is damaged or blocked, preventing fluid from draining properly. This leads to swelling, skin changes, discomfort, infections like cellulitis, and even severe mobility issues. Lipedema, meanwhile, is a genetic, hormonal condition that causes disproportionate fat buildup in the lower body. It often worsens with hormonal changes like puberty, pregnancy, or menopause, and cannot be reversed with diet or exercise. Jameka said: 'People need to know this isn't their fault." 'You can be doing everything right and still be gaining weight because your body is holding fluid and fat in ways you can't control.' By the time Jameka hit her peak weight, her legs were so swollen she could no longer walk unaided. 6 'I needed help with everything, bathing, dressing, even going to the bathroom. I felt helpless. I felt humiliated, she says.' 'I've worked as a caregiver and nursing assistant since 2010. But when my health declined, I had to take a full year off for surgeries and recovery.' During her most intense recovery period, complications arose. 'I spent a month in a nursing home after one of my surgeries,' she shared. 'I developed infections that nearly set me back completely. It was one of the hardest times in my life.' Eventually, she was admitted to a care facility, no longer able to manage daily life at home. 'I became a resident in a nursing home. That was my rock bottom.' But instead of giving up, she made a decision: if she couldn't walk, she'd crawl. If she couldn't do everything at once, she'd do something. 'Every day I told myself, 'Just one thing, Jameka. Just do one thing today'.' That one thing turned into another. And another. And slowly, the weight began to drop. Today, Jameka has lost more than half her body weight through lifestyle changes, physical therapy, and a series of targeted liposuction surgeries to remove damaged lymphatic tissue from her legs. The 5 best exercises to lose weight By Lucy Gornall, personal trainer and health journalist EXERCISE can be intimidating and hard to devote yourself to. So how do you find the right workout for you? As a PT and fitness journalist, I've tried everything. I've taken part in endless fitness competitions, marathons and I maintain a regime of runs, strength training and Pilates. Fitness is so entrenched in my life, I stick to it even at Christmas! The key is finding an activity you love that can become a habit. My top five forms of exercise, especially if you're trying to lose weight, are: Walking Running Pilates High-intensity interval training (HIIT) Strength training She now walks without assistance and has returned to work, not as a patient, but as a Certified Nursing Assistant. 'I went from being cared for to caring for others. That's the full-circle moment that keeps me going.' Her daughter, 15-year-old Jamya, has been by her side throughout. 'She's my reason. Every time I wanted to quit, I thought of her,' says Jameka. 'I still have loose skin. I still have bad days. But now I love the woman in the mirror. Because I know what she's been through.' One of her most powerful messages was 'Stop waiting for someone to clap for you. Clap for your damn self.' She's now an advocate for lymphedema and lipedema awareness, especially in underrepresented communities. 'We need more education. More compassion. More doctors who know what they're talking about. Too many of us are suffering in silence,' she said. Jameka now has nearly 100,000 Instagram followers as @meekmeek2u_ but also hopes to write a book about her battle and speak publicly to educate others about these often-hidden illnesses. For anyone living with pain, swelling, or shame, her message is loud and clear: 'You're not lazy. You're not broken. You're not alone. Keep going.' 6 6 6
The Independent
a day ago
- The Independent
‘Game-changing' new Alzheimer's drug could slow progression of disease
An Alzheimer's drug that clears away plaque build-up in the brain could slow progression of the disease and delay the onset of symptoms, early trials have shown. There is currently no cure for the disease, which can severely affect memory and impact people's ability to carry out daily tasks, and the medicines available can only reduce symptoms. But a new drug called Trontinemab is showing promising results, the Alzheimer's Association International Conference in Toronto was told. The drug has been tested on a small number of patients, but 49 out of 54 with early-stage Alzheimer's showed signs of improvement within 28 weeks during a trial, according to Roche, the pharmaceutical company behind the drug. Researchers said 91 per cent of the participants showed a reduction in clusters of protein on their brains, known as amyloid plaques – a key marker of Alzheimer's. Alzheimer's is thought to be caused by an abnormal build-up of this protein around brain cells, while another protein called tau forms tangles within brain cells. These can interrupt the chemical messengers responsible for sending signals between brain cells, according to the NHS. The new drug was found to reduce amyloid proteins to a level so low that scan results on patients taking it for seven months were considered to be 'amyloid negative'. It is thought that the clearance of plaques slows down the progression of the disease and delays the onset of symptoms. 'Alzheimer's disease represents one of the greatest challenges in healthcare today, and tackling it requires early detection and effective therapeutics,' Dr Levi Garraway, chief medical officer of Roche, said. He added: 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention.' Professor Sir John Hardy, the chairman of molecular biology of neurological disease at University College London's Institute of Neurology, who was not involved in the trial, told The Telegraph the drug was a 'massive improvement' and works faster than other Alzheimer's drugs on the market. 'There is no doubt this could be game-changing. We hope that if we can use these drugs to people early, we can halt the progression of disease, even before people have symptoms. Now we need to see the size of the clinical effect,' he said. However, the drug does have some side effects, with five participants of 149 (3 per cent) suffering from lesions or swelling in their brains after taking it. But all the participants recovered, and it was considered to be safer than other Alzheimer's drugs that have resulted in 17 per cent of participants experiencing similar side effects. The final part of the trial, which will test the drug on a large number of patients, is yet to be carried out. But if it is successful, health bodies in the UK will need to decide whether it is cost-effective enough to use on the NHS. An estimated 982,000 people are living with some form of dementia, including Alzheimer's, in the UK, with the disease most common in people over the age of 65. But more than a third of people with the condition do not have a diagnosis. The number of those with the disease is expected to rise to 1.4 million by 2040, according to the Alzheimer's Society.
Reuters
a day ago
- Reuters
Lilly's cancer drug more effective than AbbVie's in head-to-head study
July 29 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's (ABBV.N), opens new tab Imbruvica when tested in patients with a type of blood cancer.
